statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare...

FNAIT Systematic Literature Review and Meta-Analysis Presented at the Academy of Managed Care Pharmacy 2024 Annual Meeting

Rallybio partners with Johnson & Johnson to develop therapies targeting fetal and neonatal alloimmune thrombocytopenia, receiving $6.6 million investment. Phase 2 study for RLYB212 set for 2024.
read...

Rare Disease-Focused Rallybio Inks Development Pact With Johnson & Johnson, Stock Shoots Higher

Shares of Rallybio Corporation (NASDAQ: RLYB) rose sharply in today's pre-market trading after the company announced a collaboration with Johnson & Johnson to advance therapeutics for pregnant...

Why Rallybio Shares Are Trading Higher By Around 78%; Here Are 20 Stocks Moving Premarket

Rallybio Announces Collaboration to Advance Therapeutic Solutions for Pregnant Individuals at Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)

Rallybio Announces FNAIT Systematic Literature Review to be Presented at the AMCP 2024 Annual Meeting

Rallybio Co. (NASDAQ:RLYB  Free Report)  Investment analysts at HC Wainwright boosted their Q1 2024 earnings per share (EPS) estimates for shares of Rallybio in a research note issued...

Rallybio Co. (NASDAQ:RLYB) Expected to Earn Q1 2024 Earnings of ($0.52) Per Share

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Rallybio price target lowered by $3 at H.C. Wainwright, here's why

Rallybio Reports Fourth Quarter and Full Year 2023 Financial Results

Rallybio to Present at the TD Cowen 44th Annual Health Care Conference

Rallybio (NASDAQ:RLYB  Free Report) had its price target reduced by HC Wainwright from $17.00 to $12.00 in a report published on Wednesday morning, Benzinga reports. They currently have a buy...

Rallybio (NASDAQ:RLYB) Given New $12.00 Price Target at HC Wainwright

Rallybio Corp. engages in the identification, research and development, and manufacture of clinical biotechnology products and therapies for severe and rare diseases. Its product candidates focus on the areas of fetal and neonatal disorders, hematology, immuno-inflammation, and metabolic disease. The company was founded by Martin W. Mackay, Stephen Uden, and Jeffrey M. Fryer in January 2018 and is headquartered in New Haven, CT.

Rallybio Corp

Volume	227,968.00
52-Wk High	$9.14
52-Wk Low	$1.23

RLYB Rallybio Corp

About

Feed

News

Earnings

Fundamentals